Institutional Investors Retreat from Vericel Stock

Vericel Corporation (NASDAQ: VCEL) is facing a notable shift in investor sentiment, with significant institutional selling and a planned insider transaction creating downward pressure. This follows a substantial decline in the share price during Tuesday’s trading session.

The stock showed little movement in early Wednesday trading, hovering near $35.36. Market attention now turns to the company’s upcoming presentation at a major healthcare conference later this week.

Raymond James Financial Inc. substantially reduced its stake in Vericel during the first quarter, cutting its position by 30.0%. The institutional investor sold 153,558 shares and now maintains a holding of 358,661 shares valued at approximately $16 million.

This significant divestment coincided with a sharp price decline. On Tuesday, Vericel shares dropped $1.41, or 3.9%, to close Read more...